NEW YORK, Oct. 24 - Xanthon has won a patent in Australia that covers a method of directly detecting biomolecules through a “transition-metal-mediated, catalytic, oxidation-reduction reaction,” the company said on Wednesday.

The patent, numbered 724,600 and entitled "Electrochemical detection of nucleic acid hybridization," is owned by the University of North Carolina at Chapel Hill and is exclusively licensed to Xanthon on a worldwide basis.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.